Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07670234

Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions

The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.

The main questions it aims to answer :

* What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile? * Are there any potential drug interactions between dietary supplements and anticancer medications?

Participants will:

* Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics. * Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication). * Report any perceived adverse effects related to dietary supplement use to assess tolerance. * Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut National d'Oncologie

Rabat, Morocco

Location status: Recruiting

Location contact

Sihame Lkhoyaali, Professor of Medical Oncology

CONTACT

[email protected]

+212 668-270035

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.
  • Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).
  • Adult patients : >=18

Exclusion criteria

  • Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.
  • Failure or refusal to provide written informed consent.

Treatment and study plan

Dietary Supplement Use Assessment

Behavioral

Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.

Primary outcomes

  1. Prevalence of Dietary Supplement Use and Tolerance

    Time frame: At enrollment

    Assessment of the prevalence of dietary supplement use among cancer patients and evaluation of adverse effects associated with dietary supplement consumption.

  2. Potential Drug-Supplement Interactions

    Time frame: At enrollment or single study visit

    Assessment of potential interactions between dietary supplements and anticancer medications

Secondary outcomes

  1. Potential Drug-Supplement Interactions Assessed by Artificial Intelligence

    Time frame: At enrollment or Single study visit

    Assessment of potential interactions between dietary supplements and anticancer treatments using Hedrine software.

Study contacts

Contact information is provided by the study sponsor or research team.

Badiaa Batlamous

CONTACT

+212 693572066

Sihame Lkhoyaali, Professor of Medical Oncology

CONTACT

[email protected]

+212 668-270035

Sponsors and collaborators

Lead sponsor

Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)

Other

Registry information

Official study title

Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software

Acronym: Dietary Supple

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jun 26, 2026
Registry last updated
Jun 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.